A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial To Study The Efficacy And Safety Of Mk-8931 In Subjects With
Posted Date: May 15, 2019
- Investigator: Muhammad Aslam
- Type of Study: Drug
The purpose of this study is to: ? test the safety and how well a person tolerates two doses of MK-8931 in the treatment of subjects with aMCI due to Alzheimer?s disease (AD). ? assess the effect of two doses of MK-8931 on disease progression (disease getting worse) in subjects with aMCI due to
Criteria:
You Are Being Asked To Participate In This Study Because You Have Mild Cognitive Impairment.
Keywords:
Alzheimer's Disease, Mild Cognitive Impai, Memory, Prodromal Alzheimer', Cognitive
For More Information:
Marcelle Shidler
5135582455
shidlemd@ucmail.uc.edu